Screener
Tandem Diabetes Care TNDM Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Tandem Diabetes Care in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Tandem Diabetes Care’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001438133-26-000125
FAQ
- What is Tandem Diabetes Care's cash & equivalents?
- Tandem Diabetes Care (TNDM) reported cash & equivalents of $62.82M in Q2 2026.
- How has Tandem Diabetes Care's cash & equivalents changed year-over-year?
- Tandem Diabetes Care's cash & equivalents decreased by 2.0% year-over-year, from $64.11M to $62.82M.
- What is the long-term trend for Tandem Diabetes Care's cash & equivalents?
- Over 5 years (2020 to 2025), Tandem Diabetes Care's cash & equivalents has grown at a -0.9% compound annual growth rate (CAGR), from $94.61M to $90.63M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Tandem Diabetes Care's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude